Cinqair (reslizumab) is an intravenous (IV) infusion given by a healthcare provider to treat severe asthma in adults when other medications aren't working well enough. It's not meant for use during asthma attacks.
Cinqair (reslizumab) is a monoclonal antibody. It lowers the number of eosinophils (a type of white blood cell) and other cells responsible for inflammation. By lowering the amount of these cells, the medication prevents inflammation and makes it easier for you to breathe.
The following side effects may get better over time as your body gets used to the medication. Let your healthcare provider know immediately if you continue to experience these symptoms or if they worsen over time.
Contact your healthcare provider immediately if you experience any of the following.
Side effects that you should report to your care team as soon as possible:
Side effects that usually do not require medical attention (report these to your care team if they continue or are bothersome):
Yes, Cinqair (reslizumab) is a biologic medication. It's made from a type of rodent cell rather than chemicals.
No. Unfortunately, there's currently no cure for asthma. Cinqair (reslizumab) and other similar medications can only manage asthma symptoms and prevent asthma attacks.
Since Cinqair (reslizumab) is given as an infusion in a healthcare facility, it will likely be covered by your medical insurance. Unlike prescription insurance, it's hard to know the price of a medication or procedure before you receive it. It's likely that your out-of-pocket cost will vary depending on what type of insurance plan you have.
At this time it's not known if Cinqair (reslizumab) will harm your unborn baby. It's important to talk to your provider about family planning. Uncontrolled asthma can raise the risk of pregnancy-related complications. Ask your provider about other asthma medications that might be safer for you to use during pregnancy.
Cinqair (reslizumab) can cause some serious health issues. This risk may be even higher for certain groups. If this worries you, talk to your doctor or pharmacist about other options.
While rare, Cinqair (reslizumab) can cause a severe, life-threatening allergic reaction. During clinical trials, symptoms of allergic reactions were seen during the infusion or within 20 minutes after the infusion was completed. Your care team will monitor you for this and will treat you appropriately if you have this type of reaction. Seek medical help right away if you experience breathing problems, flushing, itching, swelling, or a fast heartbeat after your infusion. These could be signs of an allergic reaction.
Cinqair (reslizumab) isn't meant to treat sudden breathing problems or asthma attacks. Let your provider know if your asthma worsens or doesn't improve after starting Cinqair (reslizumab).
In clinical trials, people taking Cinqair (reslizumab) had a higher chance of developing cancerous tissue growth. There were many different types of cancerous tissue growth, and it was usually caught in the first 6 months of using Cinqair (reslizumab).
Cinqair (reslizumab) is not meant to replace any of your current asthma medications. If you are currently using corticosteroids, like prednisone tablets, Flovent (fluticasone) inhaler, or Qvar (beclomethasone) inhaler, don't stop taking them unless your provider tells you to. Stopping these medications too quickly can lead to unpleasant withdrawal symptoms.
Cinqair (reslizumab) can change the way your body fights off infections. If you happen to have a parasitic infection, your provider might treat the infection first before starting this medication. If you get an infection while taking Cinqair (reslizumab), your provider might pause the medication until your infection gets better.
Cinqair (reslizumab) is an intravenous (IV) infusion that must be administered by a healthcare provider. The dose is based on your weight and is usually given once every 4 weeks.